Alpha 2.0
Login Register
» Authors » Freya Meynell

Freya Meynell

Explore the profile of Freya Meynell including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 241
Followers 0
Related Specialties
Dermatology
Rheumatology
General Medicine
Top 10 Co-Authors
Catherine H Smith
Jonathan N Barker
Nick Dand
Satveer K Mahil
Richard B Warren
Christopher E M Griffiths
Francesca Capon
James B Galloway
Helen McAteer
Sam Norton
Published In
Br J Dermatol
Lancet Rheumatol
JAMA Dermatol
J Allergy Clin Immunol
JCI Insight
Affiliations
Soon will be listed here.
Recent Articles
1.
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove
Tsakok T, Saklatvala J, Rispens T, Loeff F, de Vries A, Allen M, et al.
JCI Insight . 2023 Feb; 8(4). PMID: 36810251
Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), an important cause of treatment failure. The most widely used biologic across...
2.
Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey
Quirke-McFarlane S, Weinman J, Cook E, Yiu Z, Dand N, Langan S, et al.
Br J Dermatol . 2023 Feb; 188(5):610-617. PMID: 36763806
Background: Nonadherence to immune-modifying therapy is a complex behaviour which, before the COVID-19 pandemic, was shown to be associated with mental health disorders in people with immune-mediated diseases. The COVID-19...
3.
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey
Bechman K, Cook E, Dand N, Yiu Z, Tsakok T, Meynell F, et al.
Br J Dermatol . 2022 Feb; 187(2):254-256. PMID: 35104366
No abstract available.
4.
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
Mahil S, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown M, et al.
Lancet Rheumatol . 2021 Nov; 4(1):e42-e52. PMID: 34778846
Background: COVID-19 vaccines have robust immunogenicity in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains scarce. Our previously published cohort study showed...
5.
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
Mahil S, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown M, et al.
Lancet Rheumatol . 2021 Jul; 3(9):e627-e637. PMID: 34258590
Background: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech)...
6.
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study
Mahil S, Dand N, Mason K, Yiu Z, Tsakok T, Meynell F, et al.
J Allergy Clin Immunol . 2020 Oct; 147(1):60-71. PMID: 33075408
Background: The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited....
7.
Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis
Benzian-Olsson N, Dand N, Chaloner C, Bata-Csorgo Z, Borroni R, Burden A, et al.
JAMA Dermatol . 2020 Sep; 156(11):1216-1222. PMID: 32936291
Importance: Although palmoplantar pustulosis (PPP) can significantly impact quality of life, the factors underlying disease severity have not been studied. Objective: To examine the factors associated with PPP severity. Design,...